1. Scrip
  2. >>Therapy Areas

'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout

Survival Gains In Third Line Patients

 
• By Andrew McConaghie

Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.

Gilead HQ
Gilead's $21bn acquisition of Immunomedics is set for completion by the end of 2020.

Immunomedics, Inc.’s Trodelvy (sacituzumab govitecan-hziy) has been hailed as a likely “new standard of care” thanks to impressive new overall survival data in third-line metastatic triple negative breast cancer (mTNBC).

The Phase III ASCENT study showed that the antibody-drug conjugate (ADC) doubled overall survival (OS) in heavily pre-treated patients compared with standard treatment, achieving 12

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.